Filtered By:
Therapy: Neoadjuvant Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 9982 results found since Jan 2013.

Effect and mechanism analysis of siRNA in inhibiting VEGF and its anti-angiogenesis effects in human osteosarcoma bearing rats.
CONCLUSIONS: The growth of tumor tissue in osteosarcoma bearing rats is inhibited in Ad-VEGF-siRNA group, Ad-VEGF-siRNA + neoadjuvant chemotherapy group and Ad-VEGF-siRNA + anti-angiogenesis chemotherapy group. The effect in Ad-VEGF-siRNA + neoadjuvant chemotherapy is more significant than simple biological therapy or Ad-VEGF-siRNA + anti-angiogenesis chemotherapy. PMID: 26636524 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - December 6, 2015 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Combination of survivin siRNA with neoadjuvant chemotherapy enhances apoptosis and reverses drug resistance in breast cancer MCF-7 cells
Conclusion: Survivin siRNA combined with the neoadjuvant chemotherapy can significantly enhance the sensitivity of MCF-7 cells to chemotherapeutics and cell apoptosis. This technology has important potential value in the therapeutic study of breast cancer.
Source: Journal of Cancer Research and Therapeutics - February 15, 2016 Category: Cancer & Oncology Authors: Honglin DongLuyu YaoWeilin BiFusheng WangWei SongYonggang Lv Source Type: research

SiRNA targeting PFK1 inhibits proliferation and migration and enhances radiosensitivity by suppressing glycolysis in colorectal cancer.
CONCLUSIONS: Our study indicates that high expression of PFK1 is negatively correlated with radiosensitivity in CRC and likely accelerates the proliferation and migration of CRC cells. Downregulation of PFK1 may enhance the radiosensitivity of CRC cells in vivo and in vitro by inhibiting glycolysis. PMID: 33042398 [PubMed]
Source: American Journal of Translational Research - October 13, 2020 Category: Research Tags: Am J Transl Res Source Type: research

Platinum-based chemotherapy for early triple-negative breast cancer
CONCLUSIONS: Platinum-based chemotherapy using carboplatin in the adjuvant or neoadjuvant setting improves long-term outcomes of DFS and OS in early TNBC, with no evidence of differences by subgroup. This was at the cost of more frequent chemotherapy delays and dose reductions, and greater haematological toxicity, though serious adverse events including neuropathy, febrile neutropenia or treatment-related death were not increased. These findings support the use of platinum-based chemotherapy for people with early TNBC. The optimal dose and regimen are not defined by this analysis, but there is a suggestion that similar rel...
Source: Cochrane Database of Systematic Reviews - September 8, 2023 Category: General Medicine Authors: Sofia Re Mason Melina L Willson Sam J Egger Jane Beith Rachel F Dear Annabel Goodwin Source Type: research

The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis
Conclusions: This meta-analysis demonstrated that CD44 overexpression might be an unfavorable prognostic factor for CRC patients and could be used to predict poor differentiation, lymph node metastasis and distant metastasis. Introduction Although therapies for colorectal cancer (CRC) has improved in recent years, colorectal cancer is still the third most common cause of cancer related death worldwide (1). Metastasis are observed in 25% of patients at initial diagnosis and approximately 50% of patients will develop metastasis (2). Presently, the outcome prediction and the therapy schedule determination of CRC patie...
Source: Frontiers in Oncology - April 29, 2019 Category: Cancer & Oncology Source Type: research

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
Biomark Insights. 2022 Feb 22;17:11772719221078774. doi: 10.1177/11772719221078774. eCollection 2022.ABSTRACTTriple negative breast cancer (TNBC) is a high-risk and aggressive malignancy characterized by the absence of estrogen receptors (ER) and progesterone receptors (PR) on the surface of malignant cells, and by the lack of overexpression of human epidermal growth factor 2 (HER2). It has limited therapeutic options compared to other subtypes of breast cancer. There is now a growing body of evidence on the role of immunotherapy in TNBC, however much of the data from clinical trials is conflicting and thus, challenging fo...
Source: Biomarker Insights - February 28, 2022 Category: General Medicine Authors: Sadaf Qureshi Nancy Chan Mridula George Shridar Ganesan Deborah Toppmeyer Coral Omene Source Type: research

Cocktail without hangover: in search for the optimal chemotherapy in the combined management of non-operable esophageal carcinomas.
CONCLUSIONS: More research is warranted to further increase the therapeutic ratio in non-operable esophageal cancers. PMID: 28375694 [PubMed - as supplied by publisher]
Source: Acta Oncologica - April 4, 2017 Category: Cancer & Oncology Authors: So B, Marcu LG, Olver I, Gowda R, Bezak E Tags: Acta Oncol Source Type: research